UTAH MEDICAL PRODUCTS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- UTAH MEDICAL PRODUCTS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- UTAH MEDICAL PRODUCTS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $0.00.
- UTAH MEDICAL PRODUCTS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $294.00K, a 390.00% increase year-over-year.
- UTAH MEDICAL PRODUCTS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $96.00K, a 357.14% increase year-over-year.
- UTAH MEDICAL PRODUCTS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- UTAH MEDICAL PRODUCTS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $390.00K, a 233.33% increase from fiscal 2023.
- UTAH MEDICAL PRODUCTS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $117.00K, a 44.55% decline from fiscal 2022.
- UTAH MEDICAL PRODUCTS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $211.00K, a 73.19% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $390.00K 10-K · filed 2026-03-27 |
| 2024-06-30 | $294.00K 10-Q · filed 2024-08-09 | $426.00K derived: sum of 4 quarters · filed 2026-03-27 |
| 2024-03-31 | $96.00K 10-Q · filed 2025-05-15 | $192.00K derived: sum of 4 quarters · filed 2026-03-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $117.00K 10-K · filed 2026-03-27 |
| 2023-09-30 | $36.00K 10-Q · filed 2024-11-12 | $285.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $60.00K 10-Q · filed 2024-08-09 | $269.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $21.00K 10-Q · filed 2024-08-09 | $213.00K derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $211.00K 10-K · filed 2025-03-26 |
| 2022-09-30 | $20.00K 10-Q · filed 2023-11-13 | $549.00K derived: sum of 4 quarters · filed 2024-03-26 |
| 2022-06-30 | $4.00K 10-Q · filed 2023-08-11 | $718.00K derived: sum of 4 quarters · filed 2024-03-26 |
| 2022-03-31 | $19.00K 10-Q · filed 2023-08-11 | $717.00K derived: sum of 4 quarters · filed 2024-03-26 |
| 2021-12-31 | $506.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $787.00K 10-K · filed 2024-03-26 |
| 2021-09-30 | $189.00K 10-Q · filed 2022-11-10 | $357.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $3.00K 10-Q · filed 2022-08-12 | $370.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $89.00K 10-Q · filed 2022-08-12 | $399.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $76.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-28 | $358.00K 10-K/A · filed 2023-03-28 |
| 2020-09-30 | $202.00K 10-Q · filed 2021-11-12 | $350.00K derived: sum of 4 quarters · filed 2022-03-25 |
| 2020-06-30 | $32.00K 10-Q · filed 2021-08-06 | $200.00K derived: sum of 4 quarters · filed 2022-03-25 |
| 2020-03-31 | $48.00K 10-Q · filed 2021-08-06 | $242.00K derived: sum of 4 quarters · filed 2022-03-25 |
| 2019-12-31 | $68.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-25 | $290.00K 10-K · filed 2022-03-25 |
| 2019-09-30 | $52.00K 10-Q/A · filed 2020-11-09 | $241.00K derived: sum of 4 quarters · filed 2021-03-26 |
| 2019-06-30 | $74.00K 10-Q · filed 2020-08-07 | $278.00K derived: sum of 4 quarters · filed 2021-03-26 |
| 2019-03-31 | $97.00K 10-Q · filed 2020-08-07 | $404.00K derived: sum of 4 quarters · filed 2021-03-26 |
| 2018-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | $679.00K 10-K · filed 2021-03-26 |
| 2018-09-30 | $89.00K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $200.00K 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $372.00K 10-Q · filed 2019-08-09 | |
| 2017-12-31 | $327.00K 10-K · filed 2020-03-16 | |
| 2016-12-31 | $431.00K 10-K · filed 2019-03-14 | |
| 2015-12-31 | $640.00K 10-K · filed 2018-03-06 | |
| 2014-12-31 | $926.00K 10-K · filed 2017-03-08 | |
| 2013-12-31 | $1.40M 10-K · filed 2016-03-10 | |
| 2012-12-31 | $1.94M 10-K · filed 2015-03-12 | |
| 2011-12-31 | $485.00K 10-K · filed 2014-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |